

April 6, 2023 Announcement 3047

Silver State Scripts Board (SSSB) Made Changes to Preferred Drug List (PDL) Effective April 6, 2023

The Silver State Scripts Board (SSSB) met on March 23, 2023, and voted to adopt the following changes to the Nevada Medicaid Preferred Drug List (PDL) effective April 6, 2023.

The complete PDL is posted on the <u>"Preferred Drug List"</u> webpage.

Drug Class/Program	Changes
Targeted Immunomodulator	Amjevita [®] added as non-preferred
	Infliximab added as preferred
	Siliq [®] moved to non-preferred
	Sotyktu [®] added as non-preferred
Dermatological Agents- Antipsoriatic Agents	Zoryve [®] added as non-preferred
	Vtama [®] added as non-preferred
	Sorilux [®] moved to non-preferred
	calcipotriene cream, foam, oint, soln moved to preferred
	calcipotriene/betamethasone susp added to non-
	preferred
	Vectical [®] oint removed from PDL due to manufacturer non-
	participation in Medicaid Drug Rebate Program
Anticoagulants, Oral	dabigatran added as non-preferred
	Pradaxa [®] oral pellets added as non-preferred
	Xarelto [®] susp added as preferred
Otic Quinolones	ciprofloxacin/dexamethasone added a non-preferred
Functional Gastrointestinal Disorder Drugs	Ibsrela [®] added as non-preferred
	Relistor [®] syringe moved to preferred
	Movantik [®] moved to preferred
Topical Antivirals	Abreva [®] removed from PDL due to manufacturer non-
	participation in Medicaid Drug Rebate Program
	docosanol OTC added as preferred
	acyclovir oint moved to preferred
	Zovirax [®] oint moved to non-preferred

	penciclovir added as non-preferred
Ophthalmic Quinolones	ofloxacin moved to preferred Ocuflox [®] added as non-preferred
Ophthalmic Macrolides	Azasite [®] added as non-preferred
Beta-Blockers	propranolol/HCTZ moved to non-preferred carvedilol ER moved to non-preferred Coreg CR [®] added as preferred propranolol soln added as preferred
Antihistamines- H1 Blockers Non-Sedating	cetirizine cap OTC moved to non-preferred cetirizine soln 5mg/5ml OTC moved to non-preferred fexofenadine D OTC added as non-preferred
Glucocorticoids/Long-Acting Beta-2 Adrenergic (LABA) Combination Products	vilanterol/fluticasone added as non-preferred